VX-745 Vertex Pharmaceuticals

Current Opinion in Investigational Drugs

Volumn 2, Issue 8, 2001, Pages 1070-1076

  Haddad, J J ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 5 (2,6 DICHLOROPHENYL) 2 (2,4 DIFLUOROPHENYLTHIO)PYRIMIDO[1,6 B]PYRIDAZIN 6 ONE; 5 (4 PYRIDINYL) 4 (4 FLUOROPHENYL) 1 (4 PIPERIDINYL)IMIDAZOLE; ANTIINFLAMMATORY AGENT; ISOPRAPANOL; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PREDNISOLONE; SYNAPTOPHYSIN; UNCLASSIFIED DRUG; VK 21931; VK 745;

ANTIINFLAMMATORY ACTIVITY; BINDING KINETICS; CLINICAL TRIAL; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; HUMAN; INFLAMMATION; NEUROLOGIC DISEASE; NONHUMAN; PHARMACODYNAMICS; REGULATORY MECHANISM; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; ENZYME INHIBITORS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; PYRIDAZINES; PYRIMIDINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0034887261     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (86)

1. Cytokines in chronic inflammatory arthritis: VI. Analysis of the synovial cells involved in granulocyte-macrophage colony-stimulating factor production and gene expression in rheumatoid arthritis and its regulation by IL-1 and tumor necrosis factor-α
2. Connective tissue components in synovial fibroblast cultures exposed to interleukin 1 and prostaglandin E-2
3. The synovial activation of chondrocytes: Evidence for complex cytokine interactions involving a possible novel factor
4. Production of IL-1 and IL-1 receptor antagonist and the pathological significance in lipopolysaccharide-induced arthritis in rabbits
5. Different cytokine production profiles of gamma delta T cell clones: Relation to inflammatory arthritis
6. Rheumatoid arthritis: New science, new treatment
7. Progress toward the treatment of arthritis by gene therapy
8. Suppression of intra-articular responses to interleukin-1 by transfer of the interleukin-1 receptor antagonist gene to synovium
9. Interleukin-1 receptor antagonist (IL-1ra) as a probe and as a treatment for IL-1 mediated disease
10. Annual report 1995 - Vertex Pharmaceuticals
11. Rheumatoid arthritis
12. The p38/RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis in response to tumour necrosis factor
13. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis
14. Cytokine therapy in rheumatoid arthritis
15. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis
16. Synovial interleukin-1 receptor and interleukin 1 balance in rheumatoid arthritis
17. Monoclonal anti-TNF-α antibody as a probe of pathogenesis and therapy of rheumatoid disease
18. Long-term beneficial responses to therapy with a monoclonal antibody to TNF-α in patients with rheumatoid arthritis (RA)
19. TNF-α blockade in rheumatoid arthritis: Results of a multicenter placebo-controlled, double-blind trial of chimeric anti-TNF-α monoclonal antibody (cA2) in refractory disease
20. Balance of IL-1 receptor antagonist/IL-1β in rheumatoid synovium and its regulation by IL-4 and IL-10
21. In vitro effects of 2 antirheumatic drugs on the synthesis and expression of proinflammatory cytokines in synovial membranes from patients with rheumatoid arthritis
22. A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket
23. Innovative therapies in autoimmune diseases, Washington, DC, USA
24. Cytokine combinations increase p75 tumor necrosis factor receptor binding and stimulate receptor shedding in rheumatoid synovial fibroblasts
25. Enhanced expression of tumor necrosis factor receptor mRNA and protein in mononuclear cells isolated from rheumatoid arthritis synovial joints
26. Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis
27. TNF-α inhibitors are produced spontaneously by rheumatoid and osteoarthritic synovial joint cell cultures: Evidence of feedback control of TNF-α action
28. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis
29. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic disease
30. Mitogen-activated protein (MAP) kinase regulates production of tumor necrosis factor-α and release of arachidonic acid in mast cells. Indications of communication between p38 and p42 MAP kinases
31. Inhibitors of p38 kinase
32. Regulation of stress-induced cytokine production by pyridinylimidazoles: Inhibition of CSBP kinase
33. A p38 MAP kinase inhibitor SB203580 inhibits CD28-dependent T cell proliferation and IL-2 production
34. Vertex and Kissei Pharmaceutical sign agreement to develop novel drugs to treat inflammatory and neurological diseases
35. Plasma and synovial fluid interleukin-1, interleukin-6 and substance P concentrations in rheumatoid arthritis patients effect of the nonsteroidal anti-inflammatory drugs indomethacin, diclofenac and naproxen
36. Immunolocalization of endothelial and leukocyte adhesion molecules in human rheumatoid and osteoarthritic synovial tissues
37. Synovial tissue macrophage populations and articular damage in rheumatoid arthritis
38. Expression of interferon-γ (IFN-γ), IL-10, IL-12 and transforming growth factor-β (TGF-β) mRNA in synovial fluid cells from patients in the early and late phases of rheumatoid arthritis (RA)
39. Selective activation of the mitogen-activated protein kinase subgroups c-Jun NH2 terminal kinase and p38 by IL-1 and TNF in human articular chondrocytes
40. Kinetic mechanism for p38 MAP kinase
41. The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase
42. Signal transduction therapy - IBC's fourth annual conference novel targets for therapeutic intervention, San Diego, USA
43. Kissei to collaborate with Vertex for p38 MAP kinase
44. Role of cytokines in rheumatoid arthritis
45. Selective activation of p38 mitogen-activated protein (MAP) kinase isoforms by the MAP kinase kinases MKK3 and MKK6
46. Localization of tumour necrosis factor-α in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis
47. Synovial fluid levels of tumour necrosis factor-α in the inflamed rat knee: Modulation by dexamethasone and inhibitors of matrix metalloproteinase and phosphodiesterase
48. Pharmacological effects of SB-220025, a selective inhibitor of p38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models
49. Vertex and Kissei select VX-745 as lead p38 MAP kinase inhibitor targeting inflammatory and neurological diseases
50. Extracellular signal-regulated kinase and p38 subgroups of mitogen-activated protein kinases regulate inducible nitric oxide synthase and tumor necrosis factor-α gene expression in endotoxin-stimulated primary glial cultures
51. How MAP kinases are regulated
52. p38 MAP kinase inhibitors: Progress, pitfalls and possibilities
53. ATP site-directed kinase inhibitors
54. Vertex reaches milestone in p38 MAP kinase program: Lead now in formal preclinicals
55. Potent inhibitors of the MAP kinase p38
56. Expression of cyclo-oxygenase 1 and cyclo-oxygenase 2 in human synovial tissue: Differential elevation of cyclo-oxygenase 2 in inflammatory joint disease
57. Conversion of SB 203580-insensitive MAP kinase family members to drug-sensitive forms by a single amino-acid substitution
58. Vertex announces start of clinical trial with VX-745 as new drug candidate targeting inflammatory and neurological diseases
59. Molecular basis for p38 kinase inhibitor specificity
60. Structural basis of inhibitor selectivity in MAP kinases
61. Crystal structure of p38 mitogen-activated kinase
62. Vertex begins pilot phase II clinical trial of VX-745, p38 MAP kinase inhibitor for the treatment of inflammatory disease
63. Inhibitors of p38 MAP kinase: Therapeutic intervention in cytokine-mediated diseases
64. Disease-modifying activity of SB-242235, a selective inhibitor of p38 mitogen-activated protein kinase, rat adjuvant-induced arthritis
65. Blocking cytokines with genes
66. Suppression of ex vivo cytokine production by SB-242235, a selective inhibitor of (p38) MAP kinase
67. p38 MAP kinase is a key regulator of cytokine and chemokine expression in pancreatic acinar cells
68. American Chemical Society 33rd Middle Atlantic Regional Meeting (Part I), Newark, DE, USA
69. American Chemical Society 33rd Middle Atlantic Regional Meeting (Part II), Newark, DE, USA
70. 27th National Medicinal Chemistry Symposium, Kansas City, MO, USA
71. Resolving bottlenecks in drug discovery, London, UK
72. Discovery of VX-745: A novel, orally bioavailable and selective p38 MAP kinase inhibitor
73. Discovery of VX-745: A novel, orally bioavailable and selective p38 MAP kinase inhibitor
74. Summary of the 27th National Medicinal Chemistry Symposium, Kansas City, MO, USA
75. New inhibitors of p38 kinase
76. Future trends in the treatment of rheumatoid arthritis: Cytokine targets
77. Vertex expands product pipeline with selection of four new drug candidates targeting viral infections, autoimmune and inflammatory diseases, and cardiovascular disorders
78. The effect of inhibitors of MEK1 and p38 MAP kinase on IL-1-induced expression of matrix metalloproteinases (MMPs), chemokines and adhesion molecules in synovial fibroblasts from patients with arthritis
79. Vertex Pharmaceuticals announces start of phase II clinical trial of VX-745 rheumatoid arthritis
80. Vertex Pharmaceuticals reports fourth quarter and full year 2000 financial results
81. Inhibitors of p38 MAP kinase: A new paradigm for the treatment of rheumatoid arthritis
82. Drug development pipeline
83. Vertex Pharmaceuticals reports first quarter 2001 financial results - Vertex continues to make clear progress in clinic
84. Clinical Management of Rheumatoid Arthritis - RSM Key Advances Symposia, London, UK
85. New targets in arthritis: Signal transduction and transcriptional regulation, Paris, France
86. Potential of p38 inhibitors in the treatment of rheumatoid arthritis